- Earnings per share increased 61% to $6.31, despite a $0.14 negative impact from acquired IPR&D charges.
- Gross margin increased to 85%, up 3 percentage points year-over-year, primarily due to improved production costs and favorable product mix.
- International revenue growth was strong, with Europe up 77% in constant currency, Japan up 7%, and China up 19%.
- Lilly reported a 38% revenue growth in Q2 2025 compared to Q2 2024, driven by key products including Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound.
- Marketing, selling, and administrative expenses rose 30%, and R&D expenses increased 23%, reflecting investments in new product launches and early-stage research.
- Non-GAAP performance margin improved by over 6 percentage points to 45.9% of revenue.
- U.S. revenue grew 38% driven by volume growth of Zepbound and Mounjaro, partially offset by an 8% price decline.
Related items and other data are not available for this feed item.
Dafinchi